{"id": "1337092901571014658", "creation": 1607622764.0, "user_id": "2702924176", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 0, "like_count": 5, "quote_count": 0}}, "quoted": "1337080176551792646", "text": "We are proud to announce the dosing of the first subject in our Phase 2 clinical trial for #COVID19 #DNA #vaccine candidate INO-4800 in China. Advaccine is conducting and funding the P2 trial in #China\n\n#INOVIO $INO #COVID #CEPI #CoronaVaccine #IVI #DOD #NEWS #SAFE #KORONA #Best https://t.co/JFQYqKxvqu", "first_save": 1634559108.199414, "hashtags": ["#COVID19", "#DNA", "#VACCINE", "#CHINA", "#INOVIO", "#COVID", "#CEPI", "#CORONAVACCINE", "#IVI", "#DOD", "#NEWS", "#SAFE", "#KORONA", "#BEST"]}